Anticonvulsant action of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline in immature rats: comparison with the effects on motor performance
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9190844
Knihovny.cz E-resources
- MeSH
- Anticonvulsants pharmacology MeSH
- Quinoxalines pharmacology MeSH
- Rats MeSH
- Cerebral Cortex drug effects MeSH
- Animals, Newborn MeSH
- Task Performance and Analysis MeSH
- Motor Activity drug effects MeSH
- Rats, Wistar MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline MeSH Browser
- Anticonvulsants MeSH
- Quinoxalines MeSH
Anticonvulsant action of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), a competitive antagonist at non-N-methyl-D-aspartate receptors for excitatory amino acids, was studied in a model of cortical epileptic afterdischarges (ADs) in 12-, 18- and 25-day-old rat pups with implanted electrodes. Electrical stimulation of sensorimotor cortex was repeated four times with 20-min intervals, NBQX (in doses of 10, 30, 60 or 90 mg/kg i.p.) or solvent (dimethyl sulfoxide, 1 ml/kg i.p.) were injected 10 min after the first afterdischarge. Dimethyl sulfoxide did not change the phenomena recorded; NBQX shortened ADs or at least blocked progressive prolongation observed under control conditions. Intensity of movements accompanying stimulation decreased after NBQX, and clonic movements accompanying ADs were suppressed in a dose-dependent manner. The highest dose of NBQX disabled the animals; therefore, the action of this drug on motor skills was studied in another group of animals. Even the dose of 30 mg/kg NBQX interfered with motor performance in 12- and 18-day-old rat pups, 25-day-old rat pups were more resistant to this action. NBQX exhibited only moderate antiepileptic action (suppression of progressive lengthening of ADs) at doses where unwanted side effects were absent.